首页> 外文期刊>JAMA: the Journal of the American Medical Association >Zinc gluconate lozenges for treating the common cold in children: a randomized controlled trial (see comments)
【24h】

Zinc gluconate lozenges for treating the common cold in children: a randomized controlled trial (see comments)

机译:葡萄糖酸锌锭剂用于治疗儿童普通感冒:一项随机对照试验(请参阅评论)

获取原文
获取原文并翻译 | 示例
       

摘要

CONTEXT: The common cold is one of the most frequently occurring illnesses and is responsible for substantial morbidity and economic loss. Biochemical evidence suggests that zinc may be an effective treatment, and zinc gluconate glycine (ZGG) lozenges have been shown to reduce the duration of cold symptoms in adults. OBJECTIVE: To determine the efficacy of ZGG treatment of colds in children and adolescents. DESIGN: A randomized, double-masked, placebo-controlled study. SETTING: Two suburban school districts in Cleveland, Ohio. PATIENTS: A total of 249 students in grades 1 through 12 were enrolled within the first 24 hours of experiencing at least 2 of 9 symptoms of the common cold. INTERVENTION: Zinc lozenges, 10 mg, orally dissolved, 5 times a day (in grades 1-6) or 6 times a day (in grades 7-12). MAIN OUTCOME MEASURES: Time to resolution of cold symptoms based on subjective daily symptom scores for cough, headache, hoarseness, muscle ache, nasal congestion, nasal drainage, scratchy throat, sore throat, and sneezing. RESULTS: Time to resolution of all cold symptoms did not differ significantly between students receiving zinc (n = 124) and those receiving placebo (n = 125) (median, 9 days; 95% confidence interval [CI], 8-9 days; median, 9 days, 95% CI, 7-10 days, respectively; P=.71). There were no significant differences in the time to resolution of any of the 9 symptoms studied. Compared with controls, more students in the zinc group reported adverse effects (88.6% vs 79.8%; P=.06); bad taste (60.2% vs 37.9%; P=.001); nausea (29.3% vs 16.1%; P=.01); mouth, tongue, or throat discomfort (36.6% vs 24.2%; P=.03); and diarrhea (10.6% vs 4.0%; P=.05). CONCLUSIONS: In this community-based, randomized controlled trial, ZGG lozenges were not effective in treating cold symptoms in children and adolescents. Further studies with virologic testing are needed to clarify what role, if any, zinc may play in treating cold symptoms.
机译:背景:普通感冒是最常见的疾病之一,是造成大量发病和经济损失的原因。生化证据表明锌可能是一种有效的治疗方法,而葡萄糖酸甘氨酸锌(ZGG)锭剂已被证明可以减少成年人感冒症状的持续时间。目的:确定ZGG治疗儿童和青少年感冒的疗效。设计:一项随机,双掩蔽,安慰剂对照的研究。地点:俄亥俄州克利夫兰的两个郊区学区。患者:在9例普通感冒症状中至少有2例出现的最初24小时内,共有249名1至12年级的学生入学。干预:口服含锌锭剂10毫克,每天5次(1-6年级)或每天6次(7-12年级)。主要观察指标:根据咳嗽,头痛,声音嘶哑,肌肉酸痛,鼻塞,鼻腔引流,嗓子发痒,喉咙痛和打喷嚏的主观日常症状评分,及时解决感冒症状。结果:接受锌的学生(n = 124)和接受安慰剂的学生(n = 125)的所有感冒症状缓解时间没有显着差异(中位数为9天; 95%置信区间[CI]为8-9天;平均为9天)。中位数分别为9天,95%CI,7-10天; P = .71)。在研究的9种症状中,任何一种缓解的时间均无显着差异。与对照组相比,锌组的学生报告有不良反应(88.6%比79.8%; P = .06);不良味道(60.2%vs 37.9%; P = .001);恶心(29.3%vs 16.1%; P = .01);口腔,舌头或喉咙不适(36.6%比24.2%; P = .03);和腹泻(10.6%比4.0%; P = .05)。结论:在这项基于社区的随机对照试验中,ZGG锭剂不能有效治疗儿童和青少年的感冒症状。需要进行病毒学测试的进一步研究,以弄清锌在治疗感冒症状中可能起什么作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号